3D肝脏分析软件在复杂型肝细胞癌切除术中的应用

肝脏 ›› 2025, Vol. 30 ›› Issue (3): 352-355.

3D肝脏分析软件在复杂型肝细胞癌切除术中的应用

程晓洁, 彭星华, 葛海江, 程海超, 张明, 李智峰

056002 河北邯郸市第一医院普外一科(程晓洁,葛海江),肝胆外一科(彭星华,程海超,李智峰);063000 华北理工大学附属医院急诊科

收稿日期:2023-10-15 出版日期:2025-03-31 发布日期:2025-06-16
通讯作者: 李智峰,Email: 1052410480@qq.com
基金资助:
河北省2025年度医学科学研究课题计划(20251299)

3D liver analysis software in complex hepatocellular liver cancer resection

CHENG Xiao-jie¹, PENG Xing-hua², GE Hai-jiang¹, CHENG Hai-chao², ZHANGMing³, LI Zhi-feng²

1. Department of General Surgery, First Hospital of Handan City, Hebei 056002, China;
2. Department of Hepatobiliary Surgery, First Hospital of Handan City, Hebei 056002, China;
3. Emergency Department of North China University of Science and Technology Affiliated Hospital, Hebei 063000, China

Received:2023-10-15 Online:2025-03-31 Published:2025-06-16
Contact: LI Zhi-feng, Email:1052410480@qq.com

摘要/Abstract

摘要： 目的分析3D肝脏分析软件在复杂型肝细胞癌切除术中的应用价值。方法 2020年5月—2023年3月邯郸市第一医院收治的复杂型肝细胞癌患者64例,按照随机数字表法将其分为对照组(n=32)和观察组(n=32)。对照组在术前进行超声检查,观察组在术前通过3D肝脏分析软件进行检查。结果观察组的手术时间、术中出血量、虚拟肝脏切除量、实际肝脏体积、残余肝脏体积和残余肝脏体积的标准比率分别为(311.2±72.5)min、(310.2±128.6)mL、(993.6±211.3)mL、(981.2±206.5)mL、(689.5±81.6)mL、(46.5±7.6)%,均优于对照组[分别为(352.9±85.6)min、(406.8±225.6)mL、(1171.5±245.6)mL、(1141.6±216.5)mL、(625.6±58.9)mL、(41.2±6.5)%,P<0.05];观察组甲胎蛋白、天冬氨酸氨基转移酶、丙氨酸氨基转移酶和胆红素水平分别为[(116.5±7.8)ng/mL、(22.8±8.6)IU/L、(30.65±4.6)IU/L、(6.8±2.9)μmol/L]均优于对照组[分别为(215.3±6.1)ng/mL、(35.2±11.5)IU/L、(34.62±5.3)IU/L、(13.1±2.4)μmol/L,P<0.05];术后1~6个月观察组日常生活能力量表(ADL)评分为86.8±2.9,显著高于对照组(61.1±2.4,P<0.05);观察组出血、感染、胆瘘、肝功能衰竭等并发症总发生率为(9.4%),明显低于对照组(56.3%,P<0.05)。结论将3D肝脏分析软件应用于复杂的肝细胞切除术,不仅可以优化手术和临床指标,还可以减少并发症,提高患者的日常生存率,值得在临床上应用。

关键词: 3D肝脏分析软件, 复杂型, 肝细胞癌, 切除术

Abstract: Objective To analyze the value of 3D liver analysis software in complex hepatocellular cancer resection.Methods 64 patients with hepatocellular cancer admitted to our hospital between May 2020 and March 2023 were divided into a control group (n=32) and an observation group (n=32) according to the random number table method. The control group was examined preoperatively by ultrasound and the observation group was examined preoperatively using 3D liver analysis software.Results Operating time, intraoperative bleeding, virtual liver resection volume, actual resected liver volume, residual liver volume, and standard residual liver volume in the observation group [(311.2±72.5) min, (310.2±128.6) mL, (993.6±211.3) mL, (981.2±206.5) mL, (689.5±81.6) mL, (46.5± (7.6) %] were better than those in the control group [(352.9±85.6) min, (406.8±225.6) mL, (1171.5±245.6) mL, (1141.6±216.5) mL, (625.6±58.9) mL, (41.2±6.5) %, P<0.05]. The levels of methemoglobin, glutathione, ghrelin and bilirubin in the observation group [(116.5±7.8) ng/mL, (22.8±8.6) IU/L, (30.65±4.6) IU/L, (6.8±2.9) μmol/L] were better than those in the control group [(215.3±6.1) ng/mL, (35.2±11.5) IU/L, (34.62±5.3) IU/L, (13.1±2.4) μmol/L, P<0.05]. The ability of daily living (ADL) score of the observation group at 1-6 months after surgery was 86.8 ± 2.9, significantly higher than that of the control group [(61.1±2.4), P<0.05]. The overall incidence of complications such as bleeding, infection, biliary fistula and liver failure in the observation group (9.4%) was significantly lower than that in the control group [(56.3%), P<0.05].Conclusion Applying 3D liver analysis software to complex hepatocyte resection not only optimizes surgical and clinical indices, but also reduces complications and improves daily survival of patients, which is worthy of clinical application.

Key words: 3D Liver analysis software, Complex type, Hepatocellular liver cancer, Resection

程晓洁, 彭星华, 葛海江, 程海超, 张明, 李智峰. 3D肝脏分析软件在复杂型肝细胞癌切除术中的应用[J]. 肝脏, 2025, 30(3): 352-355.

CHENG Xiao-jie, PENG Xing-hua, GE Hai-jiang, CHENG Hai-chao, ZHANGMing, LI Zhi-feng. 3D liver analysis software in complex hepatocellular liver cancer resection[J]. Chinese Hepatolgy, 2025, 30(3): 352-355.

/ 推荐

参考文献

[1] 李相成, 李长贤, 张嘉伟, 等. 多模式治疗肝细胞肝癌的共识与争议[J]. 中国实用外科杂志,2018,38(1):41-44.
[2] Vogel A, Meyer T, Sapisochin G, et.al. Hepatocellular carcinoma[J]. Lancet,2022,400(10360):1345-1362.
[3] Yang J D, Hainaut P, Gores G J, et.al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.
[4] Sim H W, Knox J. Hepatocellular carcinoma in the era of immunotherapy[J]. Curr Probl Cancer,2018,42(1):40-48.
[5] Vibert E, Schwartz M, Olthoff K M. Advances in resection and transplantation for hepatocellular carcinoma[J]. J Hepatol,2020,72(2):262-276.
[6] Hack S P, Spahn J, Chen M, et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation[J]. Future Oncol,2020,16(15):975-989.
[7] Singal A G, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends[J]. J Hepatol,2020,72(2):250-261.
[8] Goehler A, Harry Hsu T M, Lacson R, et al. Three-dimensional neural network to automatically assess liver tumor burden change on consecutive liver mris[J]. J Am Coll Radiol,2020,17(11):1475-1484.
[9] 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志,2017,33(8):1419-1431.
[10] Jänne P A, Baik C, Su W C, et al. Efficacy and safety of patritumab deruxtecan (her3-dxd) in egfr inhibitor-resistant, egfr-mutated non-small cell lung cancer[J]. Cancer Discov,2022,12(1):74-89.
[11] 李海东, 刘月伟, 王泳, 等. 综合康复治疗对脑部恶性肿瘤患者术后肢体功能及生活质量的影响[J]. 癌症进展,2019,17(13):1605-1608.
[12] Lee T K, Guan X Y, Ma S. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications[J]. Nat Rev Gastroenterol Hepatol,2022,19(1):26-44.
[13] Cheng K, Cai N, Zhu J, et al. Tumor-associated macrophages in liver cancer: from mechanisms to therapy[J]. Cancer Commun (Lond),2022,42(11):1112-1140.
[14] El Amrousy D, Elgendy E, Awad M E, et al. Three-dimensional speckle tracking echocardiography for early detection of left ventricular dysfunction in children with non-alcoholic fatty liver diseases[J]. Cardiol Young,2021,31(4):562-567.
[15] Chen C Y, Tsou Y F, Yeh Y T, et al. Advanced preoperative three-dimensional planning decreases the surgical complications of using large-for-size grafts in pediatric living donor liver transplantation[J]. J Pediatr Surg,2022,57(7):1210-1214.
[16] Li A, Tang R, Rong Z, et al. The use of three-dimensional printing model in the training of choledochoscopy techniques[J]. World J Surg,2018,42(12):4033-4038.
[17] El Razaky O, El Amrousy D, Elrifaey S, et al. Three-dimensional speckle tracking echocardiography: is it the magic wand in the diagnosis of subclinical myocardial dysfunction in children with type 1 diabetes mellitus[J]. Echocardiography,2018,35(10):1657-1663.
[18] Jeon H J, Jeong S, Choi H S, et al. A comparative study on aqueous chitosan solution and various submucosal injection fluids using a three-dimensional sensor[J]. Gut Liver,2021,15(2):217-224.
[19] 龚梅林, 刘丽丽, 冉雄, 等. 3D肝脏分析软件用于复杂型肝癌切除术前评估[J]. 中国医学影像技术,2022,38(6):884-887.